Can Cost Savings Offset Inflation & Protect Clorox's Margins?

The Clorox Company CLX is leaning on productivity initiatives and cost savings to counter persistent inflationary pressure, but near-term margin protection remains challenging. In the fourth quarter of fiscal 2026, the gross margin contracted 520 basis points year over year to 41.3%. Management attributed the decline mainly to higher-than-normal inflation and unfavorable mix, which more than offset benefits from cost-saving initiatives. The comparison also included about 150 basis points of pressure from lower operating leverage related to the ERP transition and another 150 basis points from GOJO acquisition-related inventory step-up.

Clorox continues to strengthen its cost structure. In fiscal 2026, the company expanded its cost-saving programs and established infrastructure designed to improve operational efficiency and generate funds for reinvestment. With the ERP implementation now completed, management is shifting from stabilization to optimization, with a focus on capturing productivity benefits, removing costs and realizing the system’s full potential.

Still, inflation is likely to remain a significant headwind in fiscal 2027. Clorox expects volatility in energy and commodity markets, elevated logistics expenses, and supply-chain pressures to keep input-cost inflation sticky. The company projects fiscal 2027 gross margin of 42%, with stronger-than-normal inflation and negative mix expected to more than offset holistic margin-management benefits.

Thus, cost savings should provide an important cushion, but they may not fully offset inflation in the near term. Longer term, productivity gains, pricing actions and disciplined margin management could support a gradual margin recovery.

Zacks Rundown for Clorox

CLX shares have risen 5.2% in the past three months compared with the industry and the Consumer Staples sector’s growth of 7.1% and 5.8%, respectively. The Zacks Rank #5 (Strong Sell) company has outpaced the S&P 500’s decline of 0.3% in the same period.

Clorox’s 3-Month Price Performance

Image Source: Zacks Investment Research

From a valuation standpoint, CLX is trading at a forward price-to-earnings ratio of 15.97X, lower than the industry’s 18.74X multiple.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Clorox’s fiscal 2027 and 2028 earnings implies year-over-year growth of 6% and 8.9%, respectively. Earnings estimates for fiscal 2027 and 2028 have moved down 2.8% and 1.7% in the past 30 days.

Image Source: Zacks Investment Research

Three Stocks Looking Good

The Vita Coco Company Inc. COCO is the leading coconut water brand in the United States, leveraging its strong brand equity, expanding global presence and asset-light business model to capitalize on the growing demand for healthier hydration beverages. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. 

The Zacks Consensus Estimate for Vita Coco’s current financial-year sales and earnings indicates growth of 31.6% and 64.7%, respectively, from the prior-year reported levels. COCO delivered a trailing four-quarter earnings surprise of 21.9%, on average.

National Vision Holdings, Inc. EYE is a value-focused optical retailer in the United States. The company currently carries a Zacks Rank of 2 (Buy).

The Zacks Consensus Estimate for National Vision’s current financial-year sales and earnings is expected to rise 3.8% and 22.5%, respectively, from the year-ago reported figures. EYE delivered a trailing four-quarter earnings surprise of 52.5%, on average.

Purple Innovation Inc. PRPL designs and manufactures products which include mattresses, pillows and cushions, using its patented Hyper-Elastic Polymer. The company currently carries a Zacks Rank of 2. 

The Zacks Consensus Estimate for Purple Innovation’s current financial-year sales and earnings indicates growth of 0.4% and 20.8%, respectively, from the year-ago reported numbers. PRPL delivered a trailing four-quarter earnings surprise of 21.3%, on average.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research